Tue, 26 Jan 2010 13:04:38 -0500 PeerView Oncology CME/CNE/CPE Video Podcast PVI, PeerView Institute for Medical Education http://www.peerviewpress.com Podcast Maker v1.3.8b - http://www.lemonzdream.com/podcastmaker Thought leader perspectives on current clinical advances in medicine. PeerView Press is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. en-us 2007 PeerView Press,24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://media.peerviewpress.com/000136/podcast/pvi/xml/vidOncologyCME-CNE-CPE_144.jpg PeerView Oncology CME/CNE/CPE Video Podcast http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Oncology no Ghassan K. Abou-Alfa, MD - Optimal Clinical Management of Treatment-Associated Adverse Effects in Patients With Hepatocellular Carcinoma: A Practical, Case-Focused Panel Discussion PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06869e45.m4v Wed, 30 Jun 2010 12:01:00 -0500 Science & Medicine no 00:25:30 HCC, liver cancer, hand-foot syndrome, HFS, sorafenib, sunitinib, Child-Pugh, cirrhosis CME/CNE/CPE Information - Optimal Clinical Management of Treatment-Associated Adverse Effects in Patients With Hepatocellular Carcinoma: A Practical, Case-Focused Panel Discussion PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06869CMEinfo.pdf Wed, 30 Jun 2010 12:00:00 -0500 Science & Medicine no 00:00:00 HCC, liver cancer, hand-foot syndrome, HFS, sorafenib, sunitinib, Child-Pugh, cirrhosis Eileen M. O'Reilly, MD - Expert Perspectives on Contemporary Management of Pancreatic Malignancies: Weighing the Latest Clinical Evidence PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06182e35.m4v Thu, 24 Jun 2010 12:01:00 -0500 Science & Medicine no 00:31:25 pancreatic cancer, adenocarcinoma, neuroendocrine tumors, chemotherapy, chemoradiation, targeted agents, neoadjuvant, resectable, genetics screening, pain, biliary obstruction, thromboembolism CME/CNE/CPE Information - Expert Perspectives on Contemporary Management of Pancreatic Malignancies: Weighing the Latest Clinical Evidence PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06182CMEinfo.pdf Thu, 24 Jun 2010 12:00:00 -0500 Science & Medicine no 00:00:00 pancreatic cancer, adenocarcinoma, neuroendocrine tumors, chemotherapy, chemoradiation, targeted agents, neoadjuvant, resectable, genetics screening, pain, biliary obstruction, thromboembolism Edith A. Perez, MD - Weighing the Evidence for an Expanded Role for Antiangiogenic Therapy in Metastatic Breast Cancer: An Interactive Panel Discussion PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06409e36.m4v Mon, 14 Jun 2010 12:00:00 -0500 Science & Medicine no 00:28:46 breast cancer, VEGF, antiangiogenic, angiogenesis, HER2, MBC, bevacizumab, E2100, sorafenib, HFS, RIBBON CME/CNE/CPE Information - Weighing the Evidence for an Expanded Role for Antiangiogenic Therapy in Metastatic Breast Cancer: An Interactive Panel Discussion PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06409CMEinfo.pdf Mon, 14 Jun 2010 12:01:00 -0500 Science & Medicine no 00:00:00 breast cancer, VEGF, antiangiogenic, angiogenesis, HER2, MBC, bevacizumab, E2100, sorafenib, HFS, RIBBON Maureen F. Zakowski, MD - Defining the Pathologist's Role in the Modern, Integrated Management of Advanced NSCLC: From Personalized Medicine to Frontline and Maintenance Therapy PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06522r114.m4v Fri, 11 Jun 2010 12:00:00 -0500 Science & Medicine no 00:24:33 non-small-cell lung cancer, NSCLC, pathology, histology, biomarkers, KRAS, EGFR, squamous, nonsquamous, targeted agents CME/CNE/CPE Information - Defining the Pathologist's Role in the Modern, Integrated Management of Advanced NSCLC: From Personalized Medicine to Frontline and Maintenance Therapy PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06522CMEinfo.pdf Fri, 11 Jun 2010 12:01:00 -0500 Science & Medicine no 00:00:00 non-small-cell lung cancer, NSCLC, pathology, histology, biomarkers, KRAS, EGFR, squamous, nonsquamous, targeted agents Corey J. Langer, MD, FACP - Personalizing Therapy in Advanced NSCLC: A Case-Based Illustration of How Patient and Disease Characteristics Influence Therapy Across Multiple Settings PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06557p19.m4v Mon, 07 Jun 2010 12:00:00 -0500 Science & Medicine no 00:27:26 NSCLC, lung cancer, brain metastases, EGFR mutations, nonsquamous, bevacizumab, maintenance, performance status CME/CNE/CPE Information - Personalizing Therapy in Advanced NSCLC: A Case-Based Illustration of How Patient and Disease Characteristics Influence Therapy Across Multiple Settings PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06557CMEinfo.pdf Mon, 07 Jun 2010 12:00:00 -0500 Science & Medicine no 00:00:00 NSCLC, lung cancer, brain metastases, EGFR mutations, nonsquamous, bevacizumab, maintenance, performance status Vincent A. Miller, MD - Identifying Challenges and Opportunities for Individualizing Therapy in NSCLC PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06288e40.m4v Tue, 18 May 2010 12:00:00 -0500 Science & Medicine no 00:41:40 NSCLC, lung cancer, histology, squamous, nonsquamous, pathology, EGFR, KRAS, TKI, bevacizumab, NOS CME/CNE/CPE Information - Identifying Challenges and Opportunities for Individualizing Therapy in NSCLC PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06288CMEinfo.pdf Tue, 18 May 2010 12:01:00 -0500 Science & Medicine no 00:00:00 NSCLC, lung cancer, histology, squamous, nonsquamous, pathology, EGFR, KRAS, TKI, bevacizumab, NOS Alan B. Copperman, MD - Current Shortcomings and Expanding Options for Fertility Preservation in Patients With Cancer PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06469r92.m4v Fri, 21 may 2010 12:37:05 -0500 Science & Medicine no 00:22:11 cancer, infertility, fertility preservation, chemotherapy, radiation, sperm banking, embryo, oocyte, ovarian cryopreservation, reproductive endocrinologist CME/CNE/CPE Information - Current Shortcomings and Expanding Options for Fertility Preservation in Patients With Cancer PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06469CMEinfo.pdf Fri, 21 may 2010 12:37:05 -0500 Science & Medicine no 00:00:00 cancer, infertility, fertility preservation, chemotherapy, radiation, sperm banking, embryo, oocyte, ovarian cryopreservation, reproductive endocrinologist Sagar Lonial, MD - Update on Modern Myeloma Management: What Do the Latest Data Mean for Clinical Practice? PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06713Myeloma.m4v Thu, 29 Apr 2010 15:50:24 -0500 Science, Medicine no 00:51:37 multiple myeloma, MM, lenalidomide, melphalan, thalidomide, bortezomib, IMID, proteasome inhibitor, ASCT, transplantation CME/CNE/CPE Information - Update on Modern Myeloma Management: What Do the Latest Data Mean for Clinical Practice? PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06713CMEinfo.pdf Thu, 29 Apr 2010 15:50:15 -0500 Science, Medicine no 00:00:00 multiple myeloma, MM, lenalidomide, melphalan, thalidomide, bortezomib, IMID, proteasome inhibitor, ASCT, transplantation Robert Rifkin, MD, FACP - Practical Strategies for Managing Treatment-Related Complications in Patients With Multiple Myeloma PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA04350FCp15.m4v Fri, 23 Apr 2010 15:50:24 -0500 Science, Medicine no 00:24:23 hematologic malignancies CME/CNE/CPE Information - Practical Strategies for Managing Treatment-Related Complications in Patients With Multiple Myeloma PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA04350FCCMEinfo.pdf Fri, 23 Apr 2010 15:50:15 -0500 Science, Medicine no 00:00:00 hematologic malignancies Koyamangalath Krishnan, MD, FRCP, FACP - Defining the Optimal Management of Tumor Lysis Syndrome: Weighing Guidelines and Evidence PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06483r87.m4v Tue, 20 Apr 2010 15:50:24 -0500 Science, Medicine no 00:36:31 hematologic malignancies CME/CNE/CPE Information - Defining the Optimal Management of Tumor Lysis Syndrome: Weighing Guidelines and Evidence PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06483CMEinfo.pdf Tue, 20 Apr 2010 15:50:15 -0500 Science, Medicine no 00:00:00 hematologic malignancies David M. Kastenberg, MD - Screening Colonoscopy: A Focus on Updated Guidelines and Enhancing Procedure Quality PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06512r94.m4v Thu, 08 Apr 2010 13:59:52 -0500 Science, Medicine no 00:29:04 CRC, colon cancer, colonoscopy, prep, ACG, PEG-ELS, ADR, adenoma detection, prevention CME/CNE/CPE - Screening Colonoscopy: A Focus on Updated Guidelines and Enhancing Procedure Quality PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06512CMEinfo.pdf Thu, 08 Apr 2010 13:59:46 -0500 Science, Medicine no 00:00:00 CRC, colon cancer, colonoscopy, prep, ACG, PEG-ELS, ADR, adenoma detection, prevention James J. Vredenburgh, MD - How to Optimally Employ Current and Emerging Therapies in Glioblastoma: An Interactive Debate of Clinical Issues and Controversies PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06260e34.m4v Thu, 25 Mar 2010 02:34:24 -0500 Science, Medicine no 00:22:14 glioblastoma, multiforme, GBM, temozolomide, TMZ, bevacizumab, myelotoxicity, VEGF, irinotecan, cytotoxic, brain, cancer CME/CNE/CPE Information - How to Optimally Employ Current and Emerging Therapies in Glioblastoma: An Interactive Debate of Clinical Issues and Controversies PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06260CMEinfo.pdf Thu, 25 Mar 2010 02:34:15 -0500 Science, Medicine no 00:00:00 glioblastoma, multiforme, GBM, temozolomide, TMZ, bevacizumab, myelotoxicity, VEGF, irinotecan, cytotoxic, brain, cancer Andre Goy, MD - Expanding Treatment Options for Relapsed/Refractory Follicular Lymphoma PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE05844r77.m4v Tue, 26 Jan 2010 12:58:24 -0500 Science, Medicine no 00:26:57 follicular lymphoma, NHL, rituximab, CHOP, relapsed, refractory, bendamustine, autologous, allogeneic, HSCT, CD20 CME/CNE/CPE Information - Expanding Treatment Options for Relapsed/Refractory Follicular Lymphoma PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05844CMEinfo.pdf Tue, 26 Jan 2010 12:58:15 -0500 Science, Medicine no 00:00:00 follicular lymphoma, NHL, rituximab, CHOP, relapsed, refractory, bendamustine, autologous, allogeneic, HSCT, CD20 Hope S. Rugo, MD - Current Research on New Treatments for Patients With Difficult-to-Treat Advanced Breast Cancer: An Interactive Discussion of Challenges, Opportunities, and Practical Considerations PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06139e29.m4v Fri, 18 Dec 2009 14:45:22 -0500 Science, Medicine no 00:22:35 difficult-to-treat, advanced breast cancer, triple negative, PARP inhibitors, epothilones, antiangiogenics, microtubule-targeting agents, chemotherapy-refractory CME/CNE/CPE Information - Current Research on New Treatments for Patients With Difficult-to-Treat Advanced Breast Cancer: An Interactive Discussion of Challenges, Opportunities, and Practical Considerations PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06139CMEinfo.pdf Fri, 18 Dec 2009 14:45:19 -0500 Science, Medicine no 00:00:00 difficult-to-treat, advanced breast cancer, triple negative, PARP inhibitors, epothilones, antiangiogenics, microtubule-targeting agents, chemotherapy-refractory Hans-Joachim Schmoll, MD, PhD - Re-Evaluating Therapeutic Options for the Prevention and Management of CINV PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06176r68.m4v Thu, 17 Dec 2009 15:40:46 -0500 Science, Medicine no 00:36:03 Re-Evaluating Therapeutic Options for the Prevention and Management of CINV CME/CNE/CPE Information - Re-Evaluating Therapeutic Options for the Prevention and Management of CINV PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06176CMEinfo.pdf Thu, 17 Dec 2009 15:40:43 -0500 Science, Medicine no 00:00:00 Re-Evaluating Therapeutic Options for the Prevention and Management of CINV Corey J. Langer, MD, FACP - An Interactive Debate on Maintenance Therapy in Advanced NSCLC: When Should We Use Maintenance, and Which Patients Benefit? PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06250e28.m4v Thu, 10 Dec 2009 14:59:36 -0500 Science, Medicine no 00:30:40 NSCLC, lung cancer, maintenance, pemetrexed, cetuximab, erlotinib, targeted, cytotoxic, JMEN, treatment break CME/CNE/CPE Information - An Interactive Debate on Maintenance Therapy in Advanced NSCLC: When Should We Use Maintenance, and Which Patients Benefit? PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06250CMEinfo.pdf Thu, 10 Dec 2009 14:59:34 -0500 Science, Medicine no 00:00:00 NSCLC, lung cancer, maintenance, pemetrexed, cetuximab, erlotinib, targeted, cytotoxic, JMEN, treatment break Axel Grothey, MD - Modifying Treatment, Maximizing Benefit: A Case-Based Exploration of Advanced CRC Management PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE05919r79.m4v Thu, 19 Nov 2009 13:59:52 -0500 Science, Medicine no 00:14:29 CRC, colorectal cancer, bevacizumab, cetuximab, panitumumab, EGFR, oxaliplatin, FOLFOX, FOLFIRI, irinotecan CME/CNE/CPE - Modifying Treatment, Maximizing Benefit: A Case-Based Exploration of Advanced CRC Management PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05919CMEinfo.pdf Thu, 19 Nov 2009 13:59:46 -0500 Science, Medicine no 00:00:00 CRC, colorectal cancer, bevacizumab, cetuximab, panitumumab, EGFR, oxaliplatin, FOLFOX, FOLFIRI, irinotecan Robert G. Gish, MD - Taking Stock of the Current Research in Hepatocellular Carcinoma PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE06218hcc.m4v Thu, 12 Nov 2009 14:39:24 -0500 Science, Medicine no 01:31:49 hepatocellular carcinoma, HCC, liver cancer, imaging tools, biomarkers, TACE, targeted therapy, multidisciplinary management CME/CNE/CPE Information - Taking Stock of the Current Research in Hepatocellular Carcinoma PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06218CMEinfo.pdf Thu, 12 Nov 2009 14:39:19 -0500 Science, Medicine no 00:00:00 hepatocellular carcinoma, HCC, liver cancer, imaging tools, biomarkers, TACE, targeted therapy, multidisciplinary management Mark A. Socinski, MD - Assessing Maintenance Therapy in Advanced NSCLC: Is it True Maintenance or Exposure to Active Treatment? PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the rationale for studying maintenance therapy in NSCLC settings and the clinical implications of new data on the maintenance use of active cytotoxic agents and targeted therapy in patients with advanced NSCLC. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE05904r67.m4v Fri, 25 Sep 2009 14:51:18 -0400 Science, Medicine no 00:15:09 maintenance, NSCLC, lung cancer, cytotoxic, JMEN, Fidias, nonsquamous, squamous, histology, erlotinib, advanced CME/CNE/CPE Information - Assessing Maintenance Therapy in Advanced NSCLC: Is it True Maintenance or Exposure to Active Treatment? PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05904CMEinfo.pdf Fri, 25 Sep 2009 14:51:15 -0400 Science, Medicine no 00:00:00 maintenance, NSCLC, lung cancer, cytotoxic, JMEN, Fidias, nonsquamous, squamous, histology, erlotinib, advanced Robert Rifkin, MD, FACP - Managing Treatment- and Disease-Related Complications in Multiple Myeloma PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts provide recommendations for management of disease- and treatment-related complications in multiple myeloma. In the 3 presentations, issues related to thrombosis, neuropathy, and myeloma bone disease are discussed. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA04348FCr66.m4v Mon, 21 Sep 2009 15:16:50 -0400 Science, Medicine no 00:27:54 peripheral neuropathy, bortezomib, multiple myeloma, DVT, bone disease, vincristine, VTE, LMWH CME/CNE/CPE Information - Managing Treatment- and Disease-Related Complications in Multiple Myeloma PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA04348FCCMEinfo.pdf Mon, 21 Sep 2009 15:16:47 -0400 Science, Medicine no 00:00:00 peripheral neuropathy, bortezomib, multiple myeloma, DVT, bone disease, vincristine, VTE, LMWH Vincent A. Miller, MD - The Evolving Treatment Paradigm for Advanced NSCLC: Clinical Highlights From the 2009 Oncology Meeting in Orlando PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest clinical trial data on the use of maintenance therapy, the clinical role of biomarkers in selecting the most appropriate therapy, and the potential of novel agents and combination strategies for advanced lung cancer. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05722FCs143.m4v Tue, 08 Sep 2009 15:09:27 -0400 Science, Medicine no 00:35:11 NSCLC, lung cancer, histology, PFS, pemetrexed, nonsquamous, squamous, EGFR, JMEN, SATURN, Fidias CME/CNE/CPE Information - The Evolving Treatment Paradigm for Advanced NSCLC: Clinical Highlights From the 2009 Oncology Meeting in Orlando PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05722FCCMEinfo.pdf Tue, 08 Sep 2009 15:09:26 -0400 Science, Medicine no 00:00:00 NSCLC, lung cancer, histology, PFS, pemetrexed, nonsquamous, squamous, EGFR, JMEN, SATURN, Fidias Jorge Cortes, MD - Questioning Clinical Assumptions in Accelerated-Phase and Blast-Crisis CML PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in CML management discuss the nature of higher risk CML and the current controversies over the criteria that define accelerated-phase and blast-crisis disease. In addition, the faculty will review the currently recommended treatment options for these patient populations and discuss the changed role of tyrosine kinase inhibitor (TKI) therapy in this more advanced setting. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05790FCe24.m4v Mon, 17 Aug 2009 13:42:34 -0400 Science, Medicine no 00:26:45 chronic myeloid leukemia, CML, TKI, targeted therapy, blast, chronic, accelerated, phase, imatinib CME/CNE/CPE Information - Questioning Clinical Assumptions in Accelerated-Phase and Blast-Crisis CML PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05790FCCMEinfo.pdf Mon, 17 Aug 2009 13:42:32 -0400 Science, Medicine no 00:00:00 chronic myeloid leukemia, CML, TKI, targeted therapy, blast, chronic, accelerated, phase, imatinib Bernard J. Escudier, MD - Expanding Options for First-Line Treatment of Advanced Kidney Cancer: How Can We Choose the Right Treatment for the Right Patient? PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert discusses the latest clinical trial data on targeted therapies for upfront treatment of metastatic RCC, assesses the clinical implications of these data, and provides recommendations for optimal integration of new agents into the current treatment paradigm for advanced RCC. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE05963s142.m4v Wed, 12 Aug 2009 15:34:59 -0400 Science, Medicine no 00:15:48 renal cell carcinoma, RCC, bevacizumab, sunitinib, sorafenib, interferon, VEGF, TKI, pazopanib, ASCO CME/CNE/CPE Information - Expanding Options for First-Line Treatment of Advanced Kidney Cancer: How Can We Choose the Right Treatment for the Right Patient? PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05963CMEinfo.pdf Wed, 12 Aug 2009 15:34:56 -0400 Science, Medicine no 00:00:00 renal cell carcinoma, RCC, bevacizumab, sunitinib, sorafenib, interferon, VEGF, TKI, pazopanib, ASCO Thomas J. Lynch Jr., MD - Can Emerging Targeted Strategies Improve Outcomes in Advanced NSCLC? PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this educational activity, 3 clinical experts in NSCLC discuss the current state and potential future directions of targeted therapy for the treatment of this disease in its advanced stages. Highlights of this discussion include the integration of these therapies into first-line treatment and maintenance regimens for advanced NSCLC, emerging molecular targeted agents for recurrent/refractory disease, and the application of predictive and prognostic markers as well as other patient-specific and disease-related characteristics for treatment selection in patients with this malignancy. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05790FCe24_2.m4v Tue, 11 Aug 2009 15:26:34 -0400 Science, Medicine no 00:26:45 non small cell lung cancer, NSCLC, gemcitabine, bevacizumab, cisplatin, pemetrexed, FLEX, erlotinib CME/CNE/CPE Information - Can Emerging Targeted Strategies Improve Outcomes in Advanced NSCLC? PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05538FCCMEinfo.pdf Tue, 11 Aug 2009 15:26:31 -0400 Science, Medicine no 00:00:00 non small cell lung cancer, NSCLC, gemcitabine, bevacizumab, cisplatin, pemetrexed, FLEX, erlotinib Maurie Markman, MD - Expert Perspectives on Challenges, Controversies, and Opportunities in Ovarian Cancer Therapy: The Present and the Future PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, a panel of experts evaluates the latest data on new targeted and cytotoxic treatment options for ovarian cancer (OC), and debates key issues, controversies, and challenges related to management of patients with OC. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE05890e030.m4v Tue, 04 Aug 2009 14:19:01 -0400 Science, Medicine no 00:25:41 ovarian, gynecologic cancer, bevacizumab, antiangiogenesis, CA-125, BRCA, bowel perforation, PLD, platinum resistance CME/CNE/CPE Information - Expert Perspectives on Challenges, Controversies, and Opportunities in Ovarian Cancer Therapy: The Present and the Future PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05890CMEinfo.pdf Tue, 04 Aug 2009 14:18:58 -0400 Science, Medicine no 00:00:00 ovarian, gynecologic cancer, bevacizumab, antiangiogenesis, CA-125, BRCA, bowel perforation, PLD, platinum resistance Henry S. Friedman, MD - Assessing the Safety and Efficacy of Emerging Therapies in Newly Diagnosed and Recurring Glioblastoma Multiforme: Latest Results From Orlando PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest clinical trial data on targeted and other new therapies for glioblastoma multiforme, assess the clinical implications of these data, and review some of the key ongoing studies that clinicians and patients should be aware of. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PPVNE05931s554.m4v Fri, 24 Jul 2009 14:45:54 -0400 Science, Medicine no 00:18:00 glioblastoma multiforme, GBM, bevacizumab, temozolomide, radiation, VEGF inhibitor, mTOR, irinotecan, antiangiogenic, immunostimulation CME/CNE/CPE Information - Assessing the Safety and Efficacy of Emerging Therapies in Newly Diagnosed and Recurring Glioblastoma Multiforme: Latest Results From Orlando PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05931CMEinfo.pdf Fri, 24 Jul 2009 14:45:35 -0400 Science, Medicine no 00:00:00 glioblastoma multiforme, GBM, bevacizumab, temozolomide, radiation, VEGF inhibitor, mTOR, irinotecan, antiangiogenic, immunostimulation Peter Hillmen, MD - Achieving Optimal Management of High-Risk CLL PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in CLL management discusses the elements of high-risk CLL and the appropriate assessment of poor-prognosis features leading to optimal therapy selection in both the upfront and relapsed/refractory setting. Treatment decisions in unsymptomatic and progressive disease will be explored, and the management of elderly individuals will also be considered. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05757FCp155.m4v Thu, 16 Jul 2009 16:08:03 -0400 Science, Medicine no 00:24:56 high-risk, chronic lymphocytic leukemia, CLL, elderly, relapsed, refractory, upfront, alemtuzumab, fludarabine CME/CNE/CPE Information - Achieving Optimal Management of High-Risk CLL PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05757FCCMEinfo.pdf Thu, 16 Jul 2009 16:08:00 -0400 Science, Medicine no 00:00:00 high-risk, chronic lymphocytic leukemia, CLL, elderly, relapsed, refractory, upfront, alemtuzumab, fludarabine Robert J. Motzer, MD - Established and Emerging Therapies for Renal Cell Carcinoma: Clinical Highlights From the 2009 Meeting in Orlando PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in oncology discuss the latest data on current and emerging therapies for advanced renal cell carcinoma. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05679FCs545.m4v Wed, 15 Jul 2009 16:01:29 -0400 Science, Medicine no 00:24:00 renal cell carinoma, RCC, AVOREN, CALGB, bevacizumab, interferon, TKI, pazopanib, sunitinib, AV-951 CME/CNE/CPE Information - Established and Emerging Therapies for Renal Cell Carcinoma: Clinical Highlights From the 2009 Meeting in Orlando PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05679FCCMEinfo.pdf Wed, 15 Jul 2009 16:01:23 -0400 Science, Medicine no 00:00:00 renal cell carinoma, RCC, AVOREN, CALGB, bevacizumab, interferon, TKI, pazopanib, sunitinib, AV-951 Axel Grothey, MD - Exploring the Potential of Targeted Adjuvant Treatment and Individualized Therapy in Colorectal Cancer: Lessons from Orlando PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in colorectal cancer (CRC) discusses the clinical implications of new and breaking data on the role of targeted agents as adjuvant therapy in early-stage CRC and the potential development of prognostic and predictive factors. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05724FCs553.m4v Thu, 09 Jul 2009 15:28:42 -0400 Science, Medicine no 00:13:54 colorectal cancer, early-stage CRC, targeted, antiangiogenic therapy, bevacizumab, FOLFOX, biomarkers, high microsatellite instability, oxaliplatin, oral fluoropyrimidines CME/CNE/CPE Information - Exploring the Potential of Targeted Adjuvant Treatment and Individualized Therapy in Colorectal Cancer: Lessons from Orlando PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05724FCCMEinfo.pdf Thu, 09 Jul 2009 15:28:37 -0400 Science, Medicine no 00:00:00 colorectal cancer, early-stage CRC, targeted, antiangiogenic therapy, bevacizumab, FOLFOX, biomarkers, high microsatellite instability, oxaliplatin, oral fluoropyrimidines William J. Gradishar, MD - Patient Scenarios for Everyday Practice: Managing Advanced HER2-Positive Breast Cancer Throughout the Disease Continuum PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in breast cancer discusses how to approach the management of a patient with metastatic HER2-positive breast cancer throughout the disease course. This program follows a patient scenario to help improve oncologists' understanding of the current standards of care and increase their awareness of emerging clinical trends in HER2-positive advanced breast cancer. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA04959FCr450.m4v Wed, 08 Jul 2009 14:27:44 -0400 Science, Medicine no 00:22:29 HER2, metastatic breast cancer, IHC, FISH, Oncotype, HERmark, endocrine therapy CME/CNE/CPE Information - Patient Scenarios for Everyday Practice: Managing Advanced HER2-Positive Breast Cancer Throughout the Disease Continuum PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA4959FCCMEinfo.pdf Wed, 08 Jul 2009 14:27:41 -0400 Science, Medicine no 00:00:00 HER2, metastatic breast cancer, IHC, FISH, Oncotype, HERmark, endocrine therapy Kenneth Anderson, MD - State of the Science in Multiple Myeloma: Which New Therapies Have Convincingly Demonstrated Improvements in Efficacy? PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest advances in the treatment of multiple myeloma, with a focus on appropriate and clinically relevant endpoints for assessing the benefit of new therapies, and results of recent clinical trials to determine if these newer agents have convincingly demonstrated improvements in efficacy. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05541FCr440.m4v Thu, 02 Jul 2009 16:19:13 -0400 Science, Medicine no 00:24:27 multiple myeloma, endpoints, bortezomib, cytogenetics, VAD, ASCT, dexamethasone, lenalidomide. ASH, ASCO CME/CNE/CPE Information - State of the Science in Multiple Myeloma: Which New Therapies Have Convincingly Demonstrated Improvements in Efficacy? PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05541FCCMEinfo.pdf Thu, 02 Jul 2009 16:19:10 -0400 Science, Medicine no 00:00:00 multiple myeloma, endpoints, bortezomib, cytogenetics, VAD, ASCT, dexamethasone, lenalidomide. ASH, ASCO Perry G. Fine, MD - Practical Considerations in Management of Chronic Pain PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. This 2-part activity focuses on some of the practical aspects of chronic pain management. Highlights from the first part of the activity include the various definitions, types, and characteristics of chronic pain. Considerations for the management of special populations with chronic pain are also discussed. The second part of the activity emphasizes the importance of patient communication, summarizes therapeutic modalities, details the rationale and challenges associated with the interdisciplinary management of chronic pain, and provides strategies for physicians when this approach is not feasible. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05601FCe028.m4v Thu, 25 Jun 2009 15:22:29 -0400 Science, Medicine no 00:24:00 chronic pain, pain, pain management, neuropathy CME/CNE/CPE Information - Practical Considerations in Management of Chronic Pain PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05601FCCMEinfo.pdf Thu, 25 Jun 2009 15:22:25 -0400 Science, Medicine no 00:00:00 chronic pain, pain, pain management, neuropathy G. David Roodman, MD, PhD - Optimizing Bone Health Management in Multiple Myeloma PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in multiple myeloma bone health management discuss the development and clinical impact of myeloma bone disease and the identification of several promising therapeutic targets within the bone microenvironment. Several other topics will be addressed, including the current recommendations for bone disease assessment and management, as well as the potential role of novel therapies with bone protective aspects. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05569FCr447.m4v Fri, 22 May 2009 15:48:00 -0400 Science, Medicine no 00:24:05 multiple myeloma bone disease, MBD, bisphosphonates, zoledronic acid, RANK Ligand, ACE, activin CME/CNE/CPE Information - Optimizing Bone Health Management in Multiple Myeloma PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05569FCCMEinfo.pdf Fri, 22 May 2009 15:47:57 -0400 Science, Medicine no 00:00:00 multiple myeloma bone disease, MBD, bisphosphonates, zoledronic acid, RANK Ligand, ACE, activin Robert J. Motzer, MD - Clinical and Research Advances in Renal Cell Carcinoma: Updates From the 2009 Genitourinary Cancers Symposium PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss recent advances in the management of kidney cancer. Latest data on new and emerging targeted treatment options will be evaluated, treatment options for RCC with sarcomatoid features will be discussed, and an evidence-based treatment algorithm for optimal integration of targeted agents into the current treatment paradigm will be provided. Additionally, research findings from studies aiming to refine the treatment of RCC will be highlighted, including those assessing the potential role of new prognostic models, clinical and genotypic variations that might influence or predict the development of toxicities associated with targeted therapies, and strategies for prevention or overcoming treatment resistance. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05349FCs515.m4v Mon, 11 May 2009 14:41:39 -0400 Science, Medicine no 00:20:45 renal carcinoma, RCC, bevacizumab, everolimus, sorafenib, sunitnib, TKI, AV-951, VEGF, prognostic models CME/CNE/CPE Information - Clinical and Research Advances in Renal Cell Carcinoma: Updates From the 2009 Genitourinary Cancers Symposium PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05349FCCMEinfo.pdf Mon, 11 May 2009 14:41:37 -0400 Science, Medicine no 00:00:00 renal carcinoma, RCC, bevacizumab, everolimus, sorafenib, sunitnib, TKI, AV-951, VEGF, prognostic models John L. Marshall, MD - Contrasting Strategies for Managing the Elderly Patient With Advanced Colorectal Cancer PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in CRC management discusses contrasting approaches to treating elderly individuals presenting with advanced disease. Two case scenarios will illustrate how therapeutic decision-making may be influenced by patient health and performance status or a patients? willingness to pursue aggressive treatment. In addition, the clinical consequences of specific comorbidities or tumor-related factors will also be explored. http://media.peerviewpress.com/000136/podcast/pvi/m4v/PA05540FCp153.m4v Wed, 29 Apr 2009 16:14:28 -0400 Science, Medicine no 00:22:11 metastatic CRC, FOLFOX, FOLFIRI, elderly, performance status, CapeOX, bevacizumab, 5-FU, panitumumab, KRAS CME/CNE/CPE Information - Contrasting Strategies for Managing the Elderly Patient With Advanced Colorectal Cancer PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05540FCCMEinfo.pdf Wed, 29 Apr 2009 16:14:26 -0400 Science, Medicine no 00:00:00 metastatic CRC, FOLFOX, FOLFIRI, elderly, performance status, CapeOX, bevacizumab, 5-FU, panitumumab, KRAS